Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Mu-Hsin Chang

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Journal of the Chinese Medical Association : JCMA|January 26, 2021
Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancerTien-Hua Chen, Peter Mu-Hsin Chang, Muh-Hwa Yang
The Oncologist|April 20, 2016
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical StudySan-Chi Chen, Peter Mu-Hsin Chang, Muh-Hwa Yang
Head & Neck|February 28, 2012
Quality of life for patients with hypopharyngeal cancer after different therapeutic modalitiesTsung-Lun Lee, Ling-Wei Wang, Peter Mu-Hsin Chang, et al.
IET Systems Biology|July 12, 2014
In silico identification of potential targets and drugs for non-small cell lung cancerChien-Hung Huang, Min-You Wu, Peter Mu-Hsin Chang, et al.
BMC Bioinformatics|January 29, 2016
Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theoryChien-Hung Huang, Peter Mu-Hsin Chang, Chia-Wei Hsu, et al.
Frontiers in Oncology|December 14, 2020
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer TherapeuticsJiun-I Lai, Yu-Jhen Tseng, Ming-Huang Chen, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 12, 2019
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathwayWei-Min Chang, Yu-Chan Chang, Yi-Chieh Yang, et al.
BMC Cancer|June 29, 2019
Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivoJia-Hong Chen, Wen-Chien Huang, Oluwaseun Adebayo Bamodu, et al.
Cancer Reports (Hoboken, N.J.)|May 29, 2021
Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trialTsung-Lun Lee, Pei-Yin Wei, Muh-Hwa Yang, et al.
Journal of the Chinese Medical Association : JCMA|May 4, 2022
Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitorsCheng-Lun Lai, Tien-Hua Chen, Peter Mu-Hsin Chang, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Journal of the Chinese Medical Association : JCMA|January 26, 2021
Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancerTien-Hua Chen, Peter Mu-Hsin Chang, Muh-Hwa Yang
The Oncologist|April 20, 2016
Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical StudySan-Chi Chen, Peter Mu-Hsin Chang, Muh-Hwa Yang
Head & Neck|February 28, 2012
Quality of life for patients with hypopharyngeal cancer after different therapeutic modalitiesTsung-Lun Lee, Ling-Wei Wang, Peter Mu-Hsin Chang, et al.
IET Systems Biology|July 12, 2014
In silico identification of potential targets and drugs for non-small cell lung cancerChien-Hung Huang, Min-You Wu, Peter Mu-Hsin Chang, et al.
BMC Bioinformatics|January 29, 2016
Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theoryChien-Hung Huang, Peter Mu-Hsin Chang, Chia-Wei Hsu, et al.
Frontiers in Oncology|December 14, 2020
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer TherapeuticsJiun-I Lai, Yu-Jhen Tseng, Ming-Huang Chen, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 12, 2019
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathwayWei-Min Chang, Yu-Chan Chang, Yi-Chieh Yang, et al.
BMC Cancer|June 29, 2019
Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivoJia-Hong Chen, Wen-Chien Huang, Oluwaseun Adebayo Bamodu, et al.
Cancer Reports (Hoboken, N.J.)|May 29, 2021
Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trialTsung-Lun Lee, Pei-Yin Wei, Muh-Hwa Yang, et al.
Journal of the Chinese Medical Association : JCMA|May 4, 2022
Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitorsCheng-Lun Lai, Tien-Hua Chen, Peter Mu-Hsin Chang, et al.
Pageof 10